GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patientâ€™s immune systemâ€™s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	11.67M 10.28M 9.74M 8.79M 16.57M 1.12B 16.79M 117M 44.85M 572M 43.84M 42.88M 1.83B	P/E 2026 *	-0.6x	P/E 2027 *	-0.81x
Enterprise Value	11.67M 10.28M 9.74M 8.79M 16.57M 1.12B 16.79M 117M 44.85M 572M 43.84M 42.88M 1.83B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	80.03%	Yield 2026 *	-	Yield 2027 *	-

09-15	GT Biopharma Receives IND Clearance For GTB-5550 In Multiple Myeloma And Provides Update On Phase 1 Trials	CI
09-14	GT Biopharma, Inc. announced that it expects to receive $30 million in funding	CI
09-11	GT Biopharma, Inc. - Special Call
08-14	GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-30	GT Biopharma Reports Integration Of AI-Based Tools Across Discovery And Engineering Of Tumor-Targeting NK Cell Engagers And Multi-Domain Proteins	CI
06-08	Gt Biopharma Advances Three Trike Drug Candidates into Human Trials and Doses First Patient in Phase 1 Trial of Gtb-5550	CI
06-01	GT Biopharma, Inc. Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	CI
05-29	GT Biopharma Advances Three Trike Drug Candidates into Human Trials	CI
05-15	GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-14	GT Biopharma announces first patient dosed in phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors	RE
05-14	Gt Biopharma Inc Announces First Patient Dosed in Phase 1 Trial of Gtb-5550, A B7-H3-Targeted Natural Killer (Nk) Cell Engager for Solid Tumors	CI
04-07	GT Biopharma, Inc. Enters into Investigator Initiated Clinical Trial Agreement with Regents of the University of Minnesota	CI
03-02	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

05/01/23	EF Hutton Starts GT Biopharma at Hold With $2 Price Target	MT
13/09/22	HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating	MT
12/08/22	Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9	MT
24/01/22	B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT
24/06/21	GT Biopharma : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating	MT

09-15	GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma	AQ
09-11	GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026	AQ
08-14	GT Biopharma Reports Second Quarter 2026 Financial Results	AQ
06-30	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs	AQ
06-12	After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell	AQ

30/04/24	Caterpillar deja París, el cacao está menos caliente
30/04/24	Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud

Oxis International Stock Euronext Paris

Stocks

US6918295014

Biotechnology & Medical Research

Valuation: Oxis International

Latest news: Oxis International

Last Transcript: Oxis International

Analysts' recommendations: Oxis International

Press Releases: Oxis International

News in other languages: Oxis International

Quotes and Performance

Managers and Directors: Oxis International

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Michael Breen CEO	Chief Executive Officer	64	02/03/2022
Alan Urban DFI	Director of Finance/CFO	57	03/06/2024

Director	Title	Age	Since
Michael Breen CHM	Chairman	64	15/12/2021
Charles Casamento BRD	Director/Board Member	79	01/05/2023
Hilary Kramer BRD	Director/Board Member	62	07/05/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OXIS INTERNATIONAL	-99.71%	-99.61%	-	-	11.67M
WUXI APPTEC CO., LTD.	+4.16%	-0.36%	+49.37%	+94.17%	74.46B
ARGENX SE	+0.99%	+2.54%	+29.42%	+83.30%	60.14B
LONZA GROUP AG	-1.25%	+0.18%	+6.81%	+35.79%	48.15B
IQVIA HOLDINGS INC.	-0.68%	-2.41%	+31.70%	+38.44%	44.25B
REVOLUTION MEDICINES, INC.	+0.51%	+2.11%	+345.01%	+679.82%	43.99B
BEONE MEDICINES AG	+0.52%	+2.67%	+10.27%	+107.04%	41.61B
CELLTRION, INC.	-0.67%	+0.17%	+7.60%	+46.37%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.16%	+36.77%	+22.78%	29.31B
INSMED INCORPORATED	+0.57%	-5.65%	-22.13%	+352.05%	24.93B
Average	-9.05%	+1.53%	+54.98%	+162.20%	44.09B
Weighted average by Cap.	+1.19%	+1.53%	+59.31%	+152.82%

	2026 *	2027 *
Net sales	-	-
Net income	-17.35M -15.28M -14.47M -13.07M -24.63M -1.66B -24.95M -173M -66.65M -850M -65.15M -63.72M -2.73B	-18.11M -15.95M -15.11M -13.64M -25.72M -1.74B -26.05M -181M -69.58M -888M -68.02M -66.53M -2.85B
Net Debt	-	-